Historically, natural products have been a rich source of lead molecules in drug discovery. In particular, products to treat infectious diseases have been developed and several reports about potentialities of essential oils (EO) against Leishmania could be found. In this study, we report the chemical characterization, anti-leishmanial effects and cytotoxicity of the EO from Artemisia absinthium L. Chemical analysis revealed the EO to be composed of 18 compounds, 11 of which were identified, accounting for 64.1% of the composition. The main component of the EO was trans-sabinyl acetate, which made up 36.7%. In vitro anti-leishmanial screening showed that the A. absinthium EO inhibited the growth of promastigotes (14.4  3.6 g/mL) and amastigotes (13.4 ± 2.4 g/mL) of L. amazonensis; while cytotoxicity evaluation caused 6 fold higher values than those for the parasites. In a model of experimental cutaneous leishmaniasis in BALB/c mice, five doses of EO at 30 mg/kg by intralesional route demonstrated control of lesion size and parasite burden (p< 0.05) compared with animals treated with glucantime and untreated mice. In conclusion, in vitro and in vivo results showed the potential of EO from A. absinthium as a promising source for lead or active compounds against Leishmania, which could be explored.
Natural products historically have been a rich source of lead molecules in drug discovery, based on their capability to create unique and diverse chemical structures. During the last decades, an important source of new chemical entities focused on plants is demonstrated by the impressive number of natural products-derived compounds which are currently either commercial or in clinical trials [1] . In particular, products to treat infectious diseases have been used, especially in developing countries. Recently, several reports have demonstrated the potential of essential oils (EO) against certain types of parasites, including Leishmania [2].
Leishmaniasis is a disease caused by protozoa of the genus Leishmania, which belongs to the order Kinetoplastida, family Trypanosomatidae. An estimated 12 million people are affected by this disease, with 2 million new cases worldwide from 98 countries [3] . Leishmaniasis has been classified as one of the most neglected diseases, and the estimated disease burden places it fourth in morbidity among the tropical infections [4] . The disease presents three main clinical forms: cutaneous (CL), mucocutaneous (MCL) and visceral (VL). The cutaneous manifestation is the most common, affecting about 1 to 1.5 million people per year and has been the most studied experimentally [5] . L. amazonensis constitutes one of the main etiological agents of CL in Brazil [5a] .
Chemotherapy of leishmaniasis still relies upon a limited number of drugs that are essentially toxic, expensive and relatively inefficient. In spite of decades of research, we are indeed far from having safe, cheap, easily administered and efficient anti-leishmanial drugs [5bc] . Considering the present scenario, development and introduction of new compounds would indeed be welcome. In the ongoing search for better leishmanicidal compounds, plant-derived products are gaining ground, being easily available and relatively cheap. Isolation and purification of active ingredients of medicinal plants was one the major forces that led to the birth of the pharmaceutical industry in the 19th century [2c]. In a continuation of our efforts to find new alternatives from natural products, we now report the chemical characterization, anti-leishmanial effects and cytotoxicity of EO from Artemisia absinthium L (Asteraceae).
Artemisia is a large and diverse genus of plants with 200 -400 species, which are known for their powerful chemical constituents in their EO [6]. One of the most studied species have been A, annua, which was the source of the antimalarial artemisinin drugs, which showed great promise, especially in treating drug-resistant malaria in combined therapy [7] . A. absinthium, a relative of Chinese A. annua, is an herbaceous and perennial plant growing to 0.8-1.2 meters [8] . Diverse effects, such as antimicrobial [9], antioxidant [10] and anticancer [11] activity of A. absinthium have been reported. However, in particular, this species has been the subject of numerous studies to test its anti-parasite effects [12] . In Cuba, pharmacological studies have been performed with A. absinthium, including assessment against Trypanosoma b. brucei, T. cruzi, L. infantum, Plasmodium falciparum, Microsporum canis, Candida albicans, Escherichia coli, Staphylococcus aureus [13] , Naegleria fowleri [14] and their toxicity to Artemia salina larvae [15] . A homeopathic tincture is commercial available as a phytopharmaceutical preparation, which is used mainly as an antiinflammatory and anti-pyretic [16] . In our study, the EO from A. absinthium was obtained and evaluated. [17, 20] . The composition of A. absinthium in this present study indicates the EO to be the sabinyl acetate chemotype, devoid of thujones, analogous to A. absinthium samples from Lithuania [21] , and very different from a previous sample from Cuba, a bornyl acetate chemotype [22] . The large concentration of unidentified compounds in the present sample suggests the presence of new structures that have not been completely elucidated. Further studies are necessary to characterize the compounds present in A. absinthium oil.
GC-MS analysis revealed
EO from A. absinthium inhibited the in vitro growth of promastigotes and amastigotes of L. amazonensis with the same IC 50 value (p > 0.05). However, cytotoxicity evaluation caused approximately 6-fold higher values than those for the parasites (Table 2) . IC 50 values of EO against intracellular amastigotes did not show statistical differences (p > 0.05) compared with GTM. [23] and Bixa orellana IC 50 = 8.5 ± 0.8 µg/mL [24] . In addition, a lower IC 50 value was also obtained compared with some EOs reported in the literature: Syzygium cumini IC 50 = 60 µg/mL [25] , Lippia sidoides IC 50 = 44 µg/mL [26] , and Ocimum gratissimum IC 50 = 100 µg/mL [27] . Compared with clinically used drugs, the same activity was observed with respect to GTM in this study, but also compared with miltefosine IC 50 = 12.5 µg/mL [28] .
In parallel, previous studies also reported anti-leishmanial activity of the EO from A. absinthium against L. aethiopica and L. donovani [29] , species that cause Old World CL and VL, respectively. Taking into account the potential in vitro results obtained and those described in the literature, the evaluation of the anti-leishmanial effect of the EO from A. absinthium was also studied in a model of CL in BALB/c mice.
Subsequent in vivo anti-leishmanial activity of the EO was assessed in a model of cutaneous leishmaniasis in BALB/c mice. Treatment of animals with Artemisia-oil controlled lesion size ( Fig. 1A) and parasite burden ( Fig. 1B ) of mice infected with L. amazonensis, showing statistical differences (p < 0.05) with respect to mice treated with GTM and untreated animals. These results were also substantiated macroscopically at 10 weeks post-infection (Fig. 1C ).
In addition, no evidence of mortality of the treated groups was observed during this study, as well as weight lost higher than 10%.
L. amazonensis-infected mice initially develop swelling at the inoculation site, which was macroscopically visible after one month of infection. Clinical studies of the treatment of CL by the intralesional route have been documented, including GTM [30] and pentostam [31] . Also, in animal models, intralesional administration has been demonstrated to be a successful alternative, particularly for natural products such as Astronium fraxinifolium [32] and Helietta apiculata [33] . In particular with EO, success has been achieved at 30 mg/kg every 4 days by the intralesional route [24, 34] , a regimen also used in the present study. The result of the in vivo experiments presented in this study indicate a lower lesion size and parasite burden in the mice treated with the EO compared with untreated animals and mice that received GTM. Although an effect of treatment with EO was observed, it does not eradicate the parasite completely, but it is known that BALB/c mice are very susceptible to infection by L. amazonensis. The underlying immune responses linked to these extreme susceptibilities are, at least in part, associated with increased interleukin 4 (IL-4) and IL-10 levels, which suppress the development of Th1 cells and inhibit IFN- secretion. Indeed, these mice have been considered a rigorous noncore model in which only the most active drugs are effective. Cure of the infection in this model, even if temporary, is usually attributed to effects of chemotherapy [35] . In addition to the direct anti-leishmanial effect caused by the EO, demonstrated in parallel due to their in vitro activity described herein, it is tempting to hypothesize that Artemisia-oil could also improve Th1 immune responses and macrophage microbicidal activation. In this sense, a previous report indicated the potent antioxidant properties of A. absinthium, which could be useful as a protective agent against associated oxidative stress disorders, including leishmaniasis [10] .
In conclusion, these in vitro and in vivo results showed the potential of EO from A. absinthium as a promising source for lead or active molecules against Leishmania. Positive features of the EO, such as the ability of most of EO components to easily diffuse through cell membranes and interact with intracellular targets, can minimize the problem of diffusing inside macrophages to inhibit intracellular parasites. Further experiments on dosage optimization and mechanism of action will be performed. EO was obtained by hydrodistillation of the aerial parts of the plant, using Clevenger type equipment.
Chemical characterization:
The A. absinthium EO was analyzed by gas chromatography coupled with mass spectrometry (GC-MS) using an Agilent 6890 GC with Agilent 5973 mass selective detector [MSD, operated in the EI mode (electron energy = 70 eV), scan range = 40-400 amu, and scan rate = 3.99 scans/sec], and an Agilent ChemStation data system. The GC column was an HP-5ms fused silica capillary with a (5% phenyl)-polymethylsiloxane stationary phase, film thickness 0.25 μm, a length of 30 m, and an internal diameter of 0.25 mm. The carrier gas was helium with a column head pressure of 48.7 kPa and a flow rate of 1.0 mL/min. Inlet temperature was 200°C and interface temperature was 280°C. The GC oven temperature program was used as follows: 40°C initial temperature, held for 10 min; increased at 3°C/min to 200°C; then increased by 2°C/min to 220°C. A 1% w/v solution of the sample in dichloromethane was prepared and 1 μL was injected using a splitless injection technique. Identification of the oil components was based on their retention indices determined by reference to a homologous series of n-alkanes, and by comparison of their mass spectral fragmentation patterns with those reported in the literature [36] and Reference drug: Glucantime (GTM) from Rhône-Poulenc Rorer (Mexico) was used as reference drug. GTM was dissolved in sterile saline solution at a concentration of 30 mg/mL.
In vitro anti-leishmanial activity of essential oil from A. absinthium:
Eleven concentrations of the EO were assayed against the promastigotes form of L. amazonensis. Exponentially growing cells (10 5 promastigotes/mL, 199 L) were distributed in 96-well plates. Either 1 µL of product dissolved in dimethylsulfoxide (DMSO) or 1 L of DMSO as control was added and incubated at 26ºC. After 3 days, the parasites were incubated for 3 h with pnitrophenyl phosphate (20 mg/mL) dissolved in 1 M sodium acetate buffer (BDH, Poole, England), pH 5.5, with 1% Triton X-100 (BDH, Poole, England) at 37ºC. The absorbance was determined in an EMS Reader MF Version 2.4-0, at a wavelength of 405 nm. The medium inhibitory concentration (IC 50 ) was obtained by fitting a sigmoidal E max model to dose-response curves [37] .
Activity of EO against the amastigote form was evaluated [38] . Macrophages were harvested from peritoneal cavities of normal BALB/c mice in RPMI medium (Sigma). A volume of 1 mL of cells was plated at 10 6 /mL in 24-well plates and incubated at 37ºC under an atmosphere of 5% CO 2 for 2 h. Non-adherent cells were removed and stationary-phase L. amazonensis promastigotes were added at a 4:1 parasite/macrophage ratio. The cultures were incubated for 4 h, washed to remove free parasites, and 1990 L of RPMI complete medium and 10 L of the different products dissolved in DMSO were added. Four dilutions 1:2 were carried out taking 1000 µL each time to test concentrations of the products ranging from 12.5 to 100 g/mL, in duplicate cultures. Control cultures was included, which were treated with DMSO and cultures were incubated during 48 h under the same conditions. Then, monolayers were fixed with absolute methanol, stained with Giemsa, and examined by light microscopy. The number of intracellular amastigotes and the percentage of infected macrophages were determined in 100 macrophages, and the infection rates were obtained by multiplying the percentage of infected macrophages by the number of amastigotes per infected macrophages. The results are expressed as percent of reduction of the infection rate in comparison with that of the controls [39] . The IC 50 was obtained from linear dose-response curves.
In parallel, the cytotoxicity of EO against peritoneal macrophages from BALB/c mice was also analyzed. Resident macrophages were collected from peritoneal cavities of normal BALB/c mice in icecold RPMI 1640 medium (SIGMA, St. Louis, Mo, USA), supplemented with antibiotics, seeded at 30,000 cells/well and allowed to adhere for 2 h at 37ºC in 5% CO 2 . After, non-adherent cells had been removed by washing with PBS, 2 L of products in DMSO were added to 98 L medium at 10% HFBS and antibiotics. Eleven dilutions of 1:2 were then prepared taking 50 µL each time and adding 50 µL of medium to test concentrations of the products ranging from 12.5 to 200 g/mL for 72 h. Cultures treated with 1 μL of DMSO were included as controls. The cytotoxicity was determined after 3 days of incubation using the colorimetric assay with 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) (SIGMA, St. Louis, MO, USA). MTT solutions were prepared at 5 mg/mL in PBS, filtered and sterilized at the time of use, and 15 μL of each solution was added to each well. After incubation for an additional 4 h, the formazan crystals were dissolved by addition of 100 μL of DMSO. The optical density was determined using an EMS Reader MF Version 2.4-0 at a test wavelength of 560 nm and a reference wavelength of 630 nm [40] . The 50% cytotoxic concentration (CC 50 ) was obtained from doseresponse curves fitted to data by means of the equation for the sigmoidal E max model. Selectivity indices (SI) were then calculated by dividing the CC 50 for peritoneal macrophages of BALB/c mice by the IC 50 for Leishmania amastigotes [41] .
In-vivo anti-leishmanial activity of essential oil from A. absinthium:
On day 0, normal BALB/c mice received subcutaneous injections in the left hind footpad of 5  10 6 stationary-phase L. amazonensis promastigotes. Four weeks post-infection (p.i.), the animals were randomly divided into 7 groups and treatment was initiated with EO at a dose of 30 mg/kg. In parallel, 3 control groups were included: treated with GTM 28 mg/kg, vehicle mixture (1:2 v/v of DMSO: saline solution) and untreated mice. The solutions were administered once a day, every 4 days, for a total of 5 administrations by the intralesional route in a volume of 20 µL.
Animals were daily monitored to retrieve deaths, and body weight was measured each 7 days during the experiment. Disease progression was monitored weekly by measuring footpad swelling of the lesion diameter between 30 and 60 days p.i., using a digital caliper. Average lesion size was calculated as the differences obtained between infected and uninfected footpads. On days 45 and 60 p.i., 3 animals of each group were killed by cervical dislocation and parasite burden determined, using the culture microtitration method [42] . A sample of the lesion was excised, weighed and homogenized in 4 mL of Schneider's medium with 10% HFBS and antibiotics. Under sterile conditions a serial four-fold dilution was prepared in plates with 96-wells containing 225 L of culture medium. After 7 days of incubation at 26ºC, plates were examined with an inverted microscope. The presence or absence of mobile promastigotes was recorded in each well. The final titer was defined as the last dilution for which the well contained at least one parasite.
The parasite burden was calculated as follows: parasite burden = (geometric mean of reciprocal titers from each duplicate/weight of homogenized cross section)  400.
Statistical analysis:
Statistical differences between IC 50 were determined using the Mann-Whitney test; while data on lesion progression and parasite burden determined by the microtitration method were analyzed by the variance test, followed by a Post Hoc Test (LDS test or planned comparison). In analysis, Statistics for Windows Program (Release 4.5, StatSoft, Inc. 1993) was used and statistical differences were classified as p < 0.05.
